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Abstract Hysterectomy remains the most common major
gynecological surgery. Postoperative sexual function is a con-
cern for many women and their partners. In this respect, a
beneficial effect of hysterectomy for benign disease indepen-
dent of surgical techniques or removal of the cervix has been
demonstrated in the past decade by the majority of studies. For
about 20 % of women, deteriorated sexual function has been
reported and current research is attempting to identify mech-
anisms and predictive factors explaining these postoperative
changes. Alternative treatments of benign uterine disorders or
uterus preserving surgery for genital prolapse appeared to
have similar outcomes in terms of sexual function.
Concomitant oophorectomy had negative effects on sexual
function and long-term health, particularly in premenopausal
women. This may not be reversed by estrogen replacement.
Hysterectomy performed for malignancy had a detrimental
effect on sexual function. Individualized risk assessment and
information should be aimed at during preoperative decision
making.
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Introduction
Hysterectomy is defined as the removal of the uterine corpus
with (total hysterectomy) or without the cervix (subtotal or
supra cervical hysterectomy). The route can be via laparoto-
my, vaginally, by applying minimally invasive techniques
(laparoscopy, robotic surgery) or a combination of the latter
two. Hysterectomy is the most common major surgical pro-
cedure performed among women in the USA after cesarean
section [1]. The indications include conditions like bleeding
problems, uterine leiomyoma, endometriosis and uterine pro-
lapse, and malignant conditions of the internal genital tract.
Concomitant bilateral oophorectomy is performed in about
50% of all cases [1, 2]. This reduces the risk of ovarian cancer
to almost zero; however, the resultant estrogen deficit may
have more detrimental effect on women’s health [2].
In the context of this review, the term “sexual function” is
used as an overall descriptive term for outcomes based on
validated and non-validated instruments. This includes sexual
activity and sexual function in terms of specific functional
aspects as well as satisfaction with sexual activity.
Hysterectomy performed to alleviate symptoms based on
somatic conditions in general improves female sexual func-
tion and quality of life, according to reviews within the past
decade [3–5]. The improvement seems to be independent of
the surgical route or whether the cervix is removed or not
(level 1B evidence) [6, 7]. In African and Asian populations, a
similarly positive outcome has been confirmed [8, 9].
Yet, reports of sexual function following hysterectomy are
inhomogeneous. One explanation for this is incomparable
study populations with different psychological and endocrine
conditions, more specifically, pre or postmenopausal women
with or without depression, and with or without bilateral oo-
phorectomy (BSO). Differing study designs add to comparison
difficulty. For instance selection bias may be present in obser-
vational studies. Kupperman et al. reported systematic differ-
ences between women opting for hysterectomy compared to
conservative treatment [10]. As a positive developement in
terms of study design, in the past decade, a number of
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randomized controlled trials (RCTs) on the topic of hysterecto-
my including sexual function have been published including a
Cochrane review [11••, 12–14, 15••]. Another complicating
factor is the multidimensional nature of female sexual function,
in particular as they age, women’s sexual function and well-
being is affected in addition to biological and psychological
factors by relationship, social, and cultural aspects [16].
A decidedly positive development is that the proportion of
studies using validated instruments to measure sexual function
has been further increasing.
Concerns about sexual function are an important
cause of anxiety for women undergoing hysterectomy
[17]. Indeed, 21 % of women with a mean age of 59
stated that the uterus is important for their sexual expe-
rience and after hysterectomy 10–20 % may experience
deterioration of their sexual function [18, 19]. Important
current topics of research are how sexual function is
affected by hysterectomy and to identify predictors for
improvement or deterioration of sexual function.
Preoperative sexual problems and/or depression have
been shown to be predictive factors for reduced desire
[19–21]. Likewise, women (online convenience sample)
reporting endometriosis to be the reason for hysterecto-
my demonstrated less improvement of sexual function,
compared to women with other (benign) indications
[22]. The authors of a recent review article summarized
possible pathways for deleterious physical effects of
hysterectomy: scar tissue in the vagina might prevent
full ballooning of the upper vagina, removed tissue may
reduce the capacity for vasocongestion and with or
without nerve damage, this could reduce arousal or
cause dyspareunia [21]. Vaginal length was not related
to sexual function [23]. Experimental evidence con-
firmed that hysterectomy caused sensory loss in the
vagina, without impacting sexual function [24]. Studies
investigating an association between postoperative de-
creased elasticity and sexual function are lacking.
It has been hypothesized that women for whom
uterine/cervical contractions are an important aspect of
orgasm, may be a subgroup more likely to experience
reduced sexual function after hysterectomy [21]. The
debate is ongoing, if and to which degree there is more
than one type of orgasm. In this context, it may be
important to differentiate between the site of stimulation
and the site of perception of orgasmic sensations [25].
Currently, there is a lack of studies, applying validated
and sensitive instruments to investigating the impact of
(the type of) hysterectomy on orgasmic function.
Interestingly, it has been demonstrated that patient educa-
tion about potential negative sexual outcomes after hysterec-
tomy (but not positive outcomes!) may enhance satisfaction
with the procedure, independent of whether sexual problems
were experienced or not [26].
Further research in the past decade about effects of hyster-
ectomy on sexual function can be grouped under the subhead-
ings following below.
Total Versus Subtotal Hysterectomy
In 2012, a comprehensive Cochrane review was published,
comparing subtotal with total hysterectomy for benign indi-
cations [11••]. Six randomized controlled trials (RCT) (per-
formed between 2002 and 2010) had outcomes related to
sexual function, with a follow-up time for up to 2 years; one
of these studies compared laparoscopic routes. The authors
found no evidence for difference in sexual satisfaction, or
patient-reported dyspareunia between subtotal and total hys-
terectomy in their meta-analysis. The authors of the Cochrane
review commented on a lack of blinded studies, causing a
degree of uncertainty with regard to subjective outcomes such
as sexual function.
One of the RCTs included in the Cochrane review, recently
completed a 5-year follow-up, and still without finding a
difference in sexual satisfaction for the two types of hysterec-
tomy [12].
In a recently published, observational study, women after
subtotal laparoscopic hysterectomy (n=788) reported more
often improved sexual function as well as sooner resumption
compared with total laparoscopic hysterectomy (n=127) [27].
Female sexual function index (FSFI) scores did not differ
between the two groups.
In summary, currently, there is no good evidence to support
the notion that subtotal hysterectomy may result in better
postoperative sexual function, compared with total hysterec-
tomy. Intercourse is likely to be resumed earlier after subtotal
hysterectomy.
Vaginal Hysterectomy or Hysterectomy for Pelvic Organ
Prolapse
Increased sexual activity was reported among 20 % of women
6 months after vaginal hysterectomy (VH) (n=791) in a
retrospective Swedish study [28].
When comparing VH plus uterosacral ligament suspension
(n=38) with robotic hysterectomy plus colpopexy (n=46), the
authors found no difference in sexual function, despite post-
operative shorter vaginas in the VH group [29]. Neither did
they find any significant change of postoperative sexual func-
tion, assessed by a condition-specific sexual function
questionnaire.
A number of studies compared different types of uterus-
sparing surgery with prolapse surgery plus hysterectomy. One
follow-up study from Italy compared uterus-sparing surgery
(hysterosacrocolpopexy) (n=32) with sacrocolpopexy plus
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hysterectomy (n=36) [30]. Sexual function, measured with
the FSFI improved in both groups, but greater improvement
was observed among women with preserved uterus. These
results should be interpreted with caution because BSO had
been performed in the hysterectomy group in addition, which
could be an important confounding factor. These results are in
contrast to prior findings from the same group, when no
significant differences in FSFI scores were reported after
uterus-sparing surgery (n=15) compared with sacrocolpopexy
plus hysterectomy (n=22); in the latter study, no BSO had
been performed, which complicates comparison [31]. Women
4–9 years after the Manchester Fothergill procedure (removal
of cervix and anterior colporrhaphy (n=98) did not differ with
regard to sexual function, compared with women after vaginal
hysterectomy (VH) (n=98) in another observational study
[32].
In summary, sexual function after VH is likely to be un-
changed or improved for most women. Alternative procedures
for uterus prolapse, involving uterus-sparing surgery, seem to
have comparable outcomes with respect to postoperative sex-
ual function.
Hysterectomy and Bilateral Oophorectomy
Studies on hysterectomy and elective bilateral oophorectomy
previously have mainly focused on cancer risk reduction and
general health issues rather than sexual function. In women
requiring hysterectomy for benign disease, preventive remov-
al of the ovaries may be routinely offered to reduce risk of
cancer or other adnexal pathology. In the USA, oophorectomy
occurs in almost half of benign hysterectomies because of
perceived risk of breast or ovarian cancer, anxiety, or financial
reasons [33••]. Since lifetime risk of 1.4 % for ovarian cancer
seems relatively low, benefits of preventive oophorectomy
may not outweigh risks. Increased perioperative complica-
tions, e.g., organ injury, circulatory, bleeding, or gastrointes-
tinal complications have been reported with BSO and hyster-
ectomy [33••]. Women may be assured that hysterectomy is
usually associated with improved quality of life and sexual
function, but concomitant oophorectomy has been shown to
compromise long-term outcomes depending on the age at
which the procedure was performed. After hysterectomy with
BSO, a 20 % breast cancer risk reduction has been demon-
strated in a large prospective study (n=66,802) from the USA
[34]. Yet, no reduced risk of all-cause mortality at any age has
been demonstrated in another large, prospective US study (n=
30,117), due to higher mortality from cardiovascular disease
and lung and colon cancer [35••]. Ovarian removal at
premenopause had significant negative impact on cardiovas-
cular, cognitive, mental, and psychosexual health [36]. The
resultant estrogen and androgen deficiency leads to more
aggravated climacteric symptoms and sexual dysfunctions,
e.g., decrease in sexual pleasure, comfort, and frequency. In
postmenopausal women, overall sexual function (sexual de-
sire, vaginal lubrication, intimacy-seeking behavior) and FSFI
scores decreased after oophorectomy [33••]. Sexual infre-
quency and multiple sexual function problems have also been
reported with increased level of menopause symptom intensi-
ty when comparing surgical and natural menopause [37].
Indeed, lower desire, arousal, lubrication, and sexual satisfac-
tion, besides more coital pain, are frequent sexual complaints
after perimenopausal oophorectomy.
Estrogen replacement therapy may enhance lubrication and
reduce vasomotor symptoms, it may not suffice to improve
overall sexual function [38].
To summarize, combining hysterectomy with bilateral oo-
phorectomy may result in impaired sexual function and in-
creased perioperative and long-term health risks, with benefits
only for women at high risk of ovarian cancer. Estrogen
replacement may not sufficiently improve sexual function
and general health. Individualized risk assessment and infor-
mation should aid in preoperative decision making.
Alternative Treatments Compared to Hysterectomy
The Society for Gynecologic Surgeons published a systematic
review in 2012, to compare hysterectomy to alternative treat-
ments for abnormal uterine bleeding (AUB) [39]. Included
were nine RCTs, comparing endometrial ablation (EA), the
levonorogestrel intrauterine system (Lng-IUS), and systemat-
ically administered medical therapy (different types of estro-
gen and/or progesterone preparations). Based on this review,
clinical practice guidelines were issued, with recommenda-
tions graded either strong or weak [40•]. Concerning sexual
function, recommendations were weak and no advantage of
any of these methods over hysterectomy was found.
Conclusion was, that the choice of treatment should be based
on additional patient preferences. In the review, one RCT
comparing Lng-IUS to hysterectomy was included, showing
no significant reduction in sexual problems after 5 years in the
two groups. However, the same RCTalso reported maintained
improvement of sexual satisfaction after 5 years among hys-
terectomized women, while it was reduced among Lng-IUS
users after both 1 and 5 years [13]. Findings of a large
observational study following 8,900 mostly premenopausal
women for up to 5 years after hysterectomy or EA are in
contrast to results of the systematic review [41]. The authors
found a higher crude and adjusted prevalence of psychosexual
problems among hysterectomized women; however, non-
validated questionnaires were used.
Uterine artery embolization (UAE) (n=88) was compared
to hysterectomy (without BSO) (n=89) in a Dutch RCT [14].
Significantly improved sexual function was only observed
after UAE; a validated questionnaire was used.
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Gonadotropin-releasing hormone agonist (GnRHa)—treat-
ment (n=42) as an alternative to hysterectomy (n=50)—was
examined in an observational study in premenopausal women
above age 45 [42]. After 2 years, no significant differences in
FSFI scores (domain or total) were observed.
Finally, an interesting study from the USA included 1,492
premenopausal women presenting with AUB, chronic pelvic
pain, or symptomatic leiomyoma and followed them for a
mean period of 3.6 years [43]. The objective was to observe
long-term effects of three defined interventions—hysterecto-
my (14 %), uterus-preserving surgery (9 %), and no surgery
(77 %). The scores for the pelvic-problem-impact-on-sex
scores improved in the long term for all three outcome groups;
most improvement was observed after hysterectomy.
In summary, most evidence collected over the past decade
show similar improvements in sexual function for alternative
treatments to hysterectomy for benign disease. Different op-
tions with defined risks and benefits should be discussed with
the woman and her preferences considered.
Hysterectomy for Cervical Cancer
As a consequence of cervical cytology screening, most wom-
en diagnosed with cervical cancer are stage 1, with an expect-
ed 5-year survival of at least 90 % in a Nordic setting [44].
Sexual problems and dysfunction are common after radical
surgery for cervical cancer; particularly, lower desire and
inadequate lubrication are reported to persist 2 years after
surgery, while other sexual problems decrease after this period
[45]. Explanations are suggested to be damage to the local
autonomous nervous system, resection of the paracolpium,
shortening of the vagina, and loss of ovarian function [46]
Individualization adapted to patient and tumor-related factors
is the current trend in cervical cancer surgery to minimize
therapy-associated morbidity [46]. As the first choice, it is
recommended to preserve nerves with minimum damage, yet
without reducing radicality (type C), as the second choice to
preserve nerves using less radical resection techniques (type
B) [46]. Nerve-sparing radical hysterectomy has been shown
to have less negative effect on sexual function than RH [47].
Radical vaginal trachelectomy (RVT) has been an option
for nearly two decades for patients with stage A1 IB1, tumor
size less than 2 cm, and a desire to preserve fertility. An
observational study from Denmark compared sexual function
among three groups: 1 year after RVT (n=18, median age
29 years) and after radical hysterectomy (RH) (n=32, median
age 42 years) to a healthy control group (n=30, median age
29 years) [48]. Postoperative sexual activity increased in the
RVT group during the follow-up and reached that of the
control group after 1 year. However, in the RVT group, sexual
distress measured with the Female Sexual Distress Scale
(FSDS) was significantly higher and FSFI scores significantly
worse, after adjusting for confounders, compared with women
both after RH and in the control group. Similar, somewhat
disappointing results with regard to RVT were confirmed by
two other studies [49, 50]. One of these studies compared RH,
RVT, and cervical conisation for early-stage cancer and
found only on the conisation group no increase in the propor-
tion of women with sexual dysfunction [50].
Likewise, vaginal extension (n=31) failed to result in im-
proved sexual function, compared to RH (n=28) without
extension in a case-control study, despite an average differ-
ence of about 4 cm [51]. Finally, laparoscopic radical hyster-
ectomy (n=20) fell short of demonstrating a beneficial effect
on postoperative sexual function as well, compared with ab-
dominal hysterectomy (n=18), in a case-control study [52].
Referral for supportive oncosexology care, a new therapeu-
tic offer aiming to improve sexual health of cancer patients
may be indicated, although no studies have been published as
yet, demonstrating their effectiveness [53, 54].
In summary the high proportion of long-time survivors
after cervical cancer may benefit from the increased amount
of research focusing on less-invasive surgical procedures with
potentially less detrimental effect on sexual function for se-
lected patients. Research in this field is hampered by the lack
of RCTs. No clear benefit in terms of improved sexual func-
tion has been demonstrated for RVT, but seems likely for
nerve-sparing techniques and for individualized
oncosexology care.
Hormone Treatment After Hysterectomy
Among postmenopausal, hysterectomized women, estrogen
therapy (ET) by vaginal route (n=30) was compared with
systemic administration (n=27) in a RCT from Taiwan,
assessing sexual function with a validated questionnaire
[55]. Vaginal blood flow improved and anorgasmia decreased
with both forms of ET application, but vaginal dryness and
dyspareunia significantly improved only with vaginal ET.
Desire or frequency of activity did not improve. An observa-
tional study from Turkey compared four groups of postmen-
opausal women after hysterectomy plus BSO: VH, using ET
(n=21), VH no ET (n=16), abdominal hysterectomy using ET
(n=28), and abdominal hysterectomy no ET (n=27) [56].
FSFI scores deteriorated in all groups, except after VH and
ET use. Type of ET use was not defined [56].
Testosterone therapy for postmenopausal, hysterectomized
women (n=71) was associated with improved desire and
arousal and increased frequency of sexual activity in a RCT
from the USA [15••]. This improvement was significant only
for the group with the highest testosterone dose (25 mg tes-
tosterone enanthate weekly, intra muscular). Sexual function
had been assessed with a validated questionnaire and some
women had undergone concomitant BSO.
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In summary, ET, in particular vaginal application, is likely
to benefit some aspects of sexual function after hysterectomy
with BSO. This may also be the case after testosterone treat-
ment, although this should be confirmed by more studies.
Vault Dehiscence After Hysterectomy
This complication has been more commonly reported in the
last decade, in particular after robot-assisted total hysterecto-
my. Based on 441 women following robotic hysterectomy for
gynecological cancer, a risk of 3 % was calculated for vault
dehiscence in combination with chemo or brachytherapy and
0.4 %, if no adjuvant therapy was given [57]. All women had
been operated at one institution. Another associated risk factor
for vault dehiscence was early resumption of intercourse.
After laparoscopic hysterectomy for benign indication, a risk
of 0.6 % was estimated, including 677 women at another
institution [58]. Sexual intercourse after 47–103 days post
surgery had been the triggering event in most cases. A large
multicenter study reviewed the charts of nearly 9,000 women,
one third each after abdominal, vaginal, and laparoscopic
hysterectomy [59]. The overall risk for vault dehiscence was
0.4 % and highest after laparoscopic surgery with intercourse
before completed healing of the vaginal cuff identified as the
main trigger among young patients.
Recommendations have beenmade to extend the period for
abstinence from deep penetrative intercourse after minimally
invasive total hysterectomy to 8–12 weeks, although dehis-
cence after penetration had occurred as late as 4 months after
surgery [60].
In summary, vault dehiscence is rare after surgery for
benign disease and an incidence of about 3 % is reported, if
laparoscopic surgery for malignancy was followed by adju-
vant therapy. Early resumption of intercourse was identified as
a risk factor. Women need to be informed about this compli-
cation and that abstinence from deep penetration may be
advisable for the first 3 postoperative months. Further evi-
dence confirming this recommendation is needed.
Hysterectomy and Partner Sexual Function
During the past decade, there continues to be a lack of research
with a focus on partner experience in the context of
hysterectomies.
This despite the findings of two qualitative studies, one
from China, the other from Brazil, that men had considerable
concerns about changes in postoperative sexuality or sexual
abstinence around the time of hysterectomy of their partner
[61, 62].
Unchanged or improved sexual satisfaction for men, with
no significant difference after total abdominal hysterectomy
(n=60) or subtotal abdominal hysterectomy (n=60), has been
reported in a retrospective study from Norway [63]. After
subtotal hysterectomy, more men noticed during intercourse
that the uterus had been removed, but none of these partners
experienced this as negative.
In summary, for the male partner, sexual function after
benign hysterectomy appears to be an important issue and
some evidence exists that men can also expect unchanged or
improved sexual satisfaction, regardless of removal of the
cervix.
Conclusion
In this review, we summarized literature from the past 10 years
regarding effects of hysterectomy on sexual function. Current
evidence suggests that hysterectomy for benign disease has
beneficial effects on sexual function and general well-being
irrespective of the surgical technique used. About 10–20 % of
women may experience deteriorated sexual function, for ex-
ample, dyspareunia or altered orgasmic experience. Risk fac-
tors for postoperative sexual dysfunction are preexistent psy-
chiatric morbidity like depression and unsatisfactory sexual
function. Health care providers should inform women
accordingly.
Hysterectomy indicated by gynecologic malignancy has
complex consequences and associated worsening of sexual
function. Lower desire and inadequate lubrication are most
persistent. For very-early-stage disease, new techniques to
preserve sexual function are promising but more RCTs need-
ed. Care providers focusing primarily on management of
malignant disease should consider referral for specialized
oncosexology counselling.
Preventive bilateral oophorectomy at the time of hysterec-
tomy for benign disease has detrimental effects on various
effects of sexual function and long-term health and has been
associated with increased mortality. Estrogen replacement
therapy after hysterectomy may reduce complaints of lubrica-
tion and dyspareunia; however, it may not suffice after con-
comitant premenopausal oophorectomy. Additionally, the
sharply declining hormone use of the past decade raises crit-
ical concerns in this context [64]. Individualized risk assess-
ment and information should aid in preoperative decision
making, also with respect to BSO.
Vault dehiscence has been reported as a complication after
3 %, in particular robot-assisted total hysterectomies for ma-
lignancy, followed by adjuvant therapy. The most common
precipitating factor appears to be intercourse, and as a
practice-based preventive measure, it is recommended to ab-
stain from intercourse for about 3 months after hysterectomy
for malignant disease.
Sexual function of the partner after hysterectomy has been
insufficiently addressed in the scientific literature, and we did
248 Curr Sex Health Rep (2014) 6:244–251
not find reports about sexual function after emergency peri-
partum hysterectomy.
In conclusion, hysterectomy ultimately eliminates bleeding
problems, coital pain, and contraception-related issues, which
may all contribute to better quality of life and sexual function.
Evidence-based strategies to prevent or minimize postopera-
tive deterioration of sexual function will benefit women facing
hysterectomy.
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